Axsome Therapeutics, Inc. Common Stock AXSM
i
Market dataready · fetched 2026-11-07T15:15:22.802Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-06T21:00:03.991945008Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-07T15:15:22.339337+00:00
Axsome Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 149.21 | 68.9% | 14.1% | 119.34 | 71.5% | 11.5% |
| 25Δ | 146.54 | 71.3% | 12.6% | 123.11 | 62.4% | 8.8% |
| 30Δ | 143.64 | 71.1% | 10.9% | 125.96 | 56.8% | 7.0% |
| 35Δ | 140.40 | 67.5% | 8.9% | 127.87 | 56.2% | 6.1% |
| 40Δ | 138.00 | 66.5% | 7.6% | 129.77 | 55.6% | 5.2% |
| 45Δ | 135.72 | 65.9% | 6.5% | 131.66 | 57.8% | 4.6% |
| 50Δ | 133.59 | 65.7% | 5.5% | 133.54 | 60.3% | 4.1% |
| 55Δ | 131.51 | 65.8% | 4.7% | 135.43 | 61.9% | 3.6% |
| 60Δ | 129.42 | 65.9% | 4.0% | 137.31 | 60.3% | 3.0% |
| 65Δ | 127.28 | 65.9% | 3.3% | 139.20 | 58.8% | 2.4% |
| 70Δ | 125.13 | 66.0% | 2.7% | 141.36 | 58.2% | 1.8% |
| 75Δ | 123.01 | 64.1% | 2.1% | 143.72 | 58.2% | 1.4% |
| 80Δ | 120.89 | 62.0% | 1.5% | 146.90 | 59.9% | 1.0% |
20Δ
- Pseudo strike
- 149.21
- IV
- 68.9%
- B/E move
- 14.1%
- Pseudo strike
- 119.34
- IV
- 71.5%
- B/E move
- 11.5%
25Δ
- Pseudo strike
- 146.54
- IV
- 71.3%
- B/E move
- 12.6%
- Pseudo strike
- 123.11
- IV
- 62.4%
- B/E move
- 8.8%
30Δ
- Pseudo strike
- 143.64
- IV
- 71.1%
- B/E move
- 10.9%
- Pseudo strike
- 125.96
- IV
- 56.8%
- B/E move
- 7.0%
35Δ
- Pseudo strike
- 140.40
- IV
- 67.5%
- B/E move
- 8.9%
- Pseudo strike
- 127.87
- IV
- 56.2%
- B/E move
- 6.1%
40Δ
- Pseudo strike
- 138.00
- IV
- 66.5%
- B/E move
- 7.6%
- Pseudo strike
- 129.77
- IV
- 55.6%
- B/E move
- 5.2%
45Δ
- Pseudo strike
- 135.72
- IV
- 65.9%
- B/E move
- 6.5%
- Pseudo strike
- 131.66
- IV
- 57.8%
- B/E move
- 4.6%
50Δ
- Pseudo strike
- 133.59
- IV
- 65.7%
- B/E move
- 5.5%
- Pseudo strike
- 133.54
- IV
- 60.3%
- B/E move
- 4.1%
55Δ
- Pseudo strike
- 131.51
- IV
- 65.8%
- B/E move
- 4.7%
- Pseudo strike
- 135.43
- IV
- 61.9%
- B/E move
- 3.6%
60Δ
- Pseudo strike
- 129.42
- IV
- 65.9%
- B/E move
- 4.0%
- Pseudo strike
- 137.31
- IV
- 60.3%
- B/E move
- 3.0%
65Δ
- Pseudo strike
- 127.28
- IV
- 65.9%
- B/E move
- 3.3%
- Pseudo strike
- 139.20
- IV
- 58.8%
- B/E move
- 2.4%
70Δ
- Pseudo strike
- 125.13
- IV
- 66.0%
- B/E move
- 2.7%
- Pseudo strike
- 141.36
- IV
- 58.2%
- B/E move
- 1.8%
75Δ
- Pseudo strike
- 123.01
- IV
- 64.1%
- B/E move
- 2.1%
- Pseudo strike
- 143.72
- IV
- 58.2%
- B/E move
- 1.4%
80Δ
- Pseudo strike
- 120.89
- IV
- 62.0%
- B/E move
- 1.5%
- Pseudo strike
- 146.90
- IV
- 59.9%
- B/E move
- 1.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 43.89% | |
| 44.56% | |
| 43.98% | |
| 43.23% | |
| 42.24% | |
| 44.15% | |
| 45.15% | |
| 46.11% | |
| 42.63% | |
| 43.02% | |
| 41.84% | |
| 42.40% | |
| 41.70% | |
| 41.27% | |
| 41.95% | |
| 42.01% | |
| 41.39% | |
| 41.60% | |
| 41.30% | |
| 43.21% | |
| 41.51% | |
| 41.80% | |
| 42.68% | |
| 46.49% | |
| 46.30% | |
| 46.97% | |
| 42.41% | |
| 42.56% | |
| 41.96% | |
| 43.43% | |
| 45.17% | |
| 44.40% | |
| 44.53% | |
| 44.64% | |
| 44.04% | |
| 44.20% | |
| 44.24% | |
| 46.05% | |
| 45.03% | |
| 45.00% | |
| 46.80% | |
| 47.19% | |
| 51.14% | |
| 55.36% | |
| 55.66% | |
| 58.03% | |
| 51.96% | |
| 51.79% | |
| 51.23% | |
| 50.70% | |
| 51.14% | |
| 52.86% | |
| 58.21% | |
| 58.44% | |
| 57.36% | |
| 58.53% | |
| 63.68% |
Biotechnology
BBIO
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
More →BCAX
Description unavailable
More →BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments. The company is…
More →BDTX
Black Diamond Therapeutics, Inc., a biotechnology company, discovers and develops small molecule tumor agnostic therapies. The company is headquartered in Cambridge, Massachusetts.
More →BEAM
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in…
More →BHVN
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops candidate products targeting neurological diseases and rare disorders in the United States. The…
More →